Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 19Recruiting 5Active not recruiting 3Unknown 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Vaginal Neoplasms × Clear all
NCT05949632 2026-06-04

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Terminated
5 enrolled 13 charts
GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT00669422 2012-10-05

ChemoFx® PRO - A Post-Market Data Collection Study

Precision Therapeutics

Terminated
2,756 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Hypersensitivity, Ovarian Neoplasms, Recurrence, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡